{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:35Z","timestamp":1791105695579,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.neuropharm.2009.12.024","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T00:55:01Z","timestamp":1263516901000},"page":"981-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys"],"prefix":"10.1016","volume":"58","author":[{"given":"Nicolas","family":"Morin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gr\u00e9goire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baltazar","family":"Gomez-Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9r\u00e8se","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2009.12.024_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/mds.870130507","article-title":"Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys","volume":"13","author":"Blanchet","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib3","first-page":"251","article-title":"Renaissance of amantadine in the treatment of Parkinson's disease","volume":"91","author":"Blanchet","year":"2003","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib4","doi-asserted-by":"crossref","first-page":"8302","DOI":"10.1523\/JNEUROSCI.23-23-08302.2003","article-title":"Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats","volume":"23","author":"Breysse","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib5","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1523\/JNEUROSCI.22-13-05669.2002","article-title":"Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism","volume":"22","author":"Breysse","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib6","first-page":"454","article-title":"Recent advances in the treatment of l-Dopa-induced dyskinesia","volume":"5","author":"Brown","year":"2002","journal-title":"IDrugs"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib8","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nrn1763","article-title":"Metabotropic glutamate receptors in the basal ganglia motor circuit","volume":"6","author":"Conn","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.brainresbull.2005.12.009","article-title":"Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease","volume":"69","author":"Dekundy","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.brainresrev.2007.11.007","article-title":"Receptor\u2013receptor interactions within receptor mosaics. Impact on neuropsychopharmacology","volume":"58","author":"Fuxe","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib12","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00702-008-0098-4","article-title":"Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats","volume":"115","author":"Gravius","year":"2008","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s002109900167","article-title":"Noradrenoceptor antagonism with idazoxan improves l-Dopa-induced dyskinesias in MPTP monkeys","volume":"361","author":"Grondin","year":"2000","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib14","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1460-9568.2006.05047.x","article-title":"Chronic high-frequency stimulation of the subthalamic nucleus and l-Dopa treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission","volume":"24","author":"Gubellini","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib15","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","article-title":"Effect of a selective glutamate antagonist on l-Dopa-induced dyskinesias in drug-naive parkinsonian monkeys","volume":"15","author":"Hadj Tahar","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1128\/AAC.19.2.226","article-title":"Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults","volume":"19","author":"Hayden","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/jpet.104.066191","article-title":"Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease","volume":"310","author":"Hill","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib18","unstructured":"Johnston, T., Fox, S., McIldowie, M., Piggott, M., Brotchie, J., 2009a. Anti-dyskinetic effects of the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. The Society for Neuroscience Annual Meeting, 2009, abstract # 530.19."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib19","unstructured":"Johnston, T., Fox, S., McIldowie, M., Piggott, M., Brotchie, J., 2009b. Anti-dyskinetic effects of the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. The Movement Disorder Society's 13th International Congress 2009, Late breaking abstract LB-16."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.nbd.2007.08.011","article-title":"Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-Dopa-induced dyskinesias in a rodent model of Parkinson's disease","volume":"29","author":"Levandis","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib22","doi-asserted-by":"crossref","first-page":"13668","DOI":"10.1073\/pnas.1835724100","article-title":"Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment","volume":"100","author":"Marino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1471-4159.2007.04456.x","article-title":"Antagonism of metabotropic glutamate receptor type 5 attenuates l-Dopa-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease","volume":"101","author":"Mela","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0079-6123(08)60454-9","article-title":"The glutamate synapse as a therapeutical target: perspectives for the future","volume":"116","author":"Meldrum","year":"1998","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib25","doi-asserted-by":"crossref","first-page":"1007S","DOI":"10.1093\/jn\/130.4.1007S","article-title":"Glutamate as a neurotransmitter in the brain: review of physiology and pathology","volume":"130","author":"Meldrum","year":"2000","journal-title":"J. Nutr."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.neuropharm.2005.04.002","article-title":"MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats","volume":"49","author":"Ossowska","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0028-3908(01)00083-1","article-title":"Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats","volume":"41","author":"Ossowska","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0306-4522(01)00297-4","article-title":"Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons","volume":"106","author":"Pisani","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.108.150425","article-title":"Pharmacological modulation of glutamate transmission in a rat model of l-Dopa-induced dyskinesia: effects on motor behavior and striatal nuclear signaling","volume":"330","author":"Rylander","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S0028-3908(03)00249-1","article-title":"Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems","volume":"45","author":"Samadi","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib31","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.neurobiolaging.2007.02.005","article-title":"mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys","volume":"29","author":"Samadi","year":"2008","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib32","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0014-2999(00)00697-X","article-title":"Effects of the prototypical mGlu(5) receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats","volume":"406","author":"Spooren","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0165-6147(00)01694-1","article-title":"Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders","volume":"22","author":"Spooren","year":"2001","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.WNF.0000232277.68501.08","article-title":"End-of-dose wearing off in Parkinson disease: a 9-question survey assessment","volume":"29","author":"Stacy","year":"2006","journal-title":"Clin. Neuropharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2009.12.024_bib35","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1002\/mds.22052","article-title":"Treatment of levodopa-induced motor complications","volume":"23","author":"Stocchi","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneur.63.2.205","article-title":"Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976\u20131990","volume":"63","author":"Van Gerpen","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2009.12.024_bib37","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2009.12.024_bib38","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.neuroscience.2009.07.060","article-title":"Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-Dopa in striatal neurons of 6-hydroxydopamine-lesioned rats","volume":"163","author":"Yamamoto","year":"2009","journal-title":"Neuroscience"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081000002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081000002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:38:59Z","timestamp":1758436739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081000002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S002839081000002X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.12.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2009.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}